GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ContraFect Corp (OTCPK:CFRXQ) » Definitions » Mohanram G-Score

ContraFect (ContraFect) Mohanram G-Score : N/A (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is ContraFect Mohanram G-Score?

ContraFect does not have enough data to calculate Mohanram G-Score.


ContraFect Mohanram G-Score Historical Data

The historical data trend for ContraFect's Mohanram G-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ContraFect Mohanram G-Score Chart

ContraFect Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Mohanram G-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

ContraFect Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Mohanram G-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of ContraFect's Mohanram G-Score

For the Biotechnology subindustry, ContraFect's Mohanram G-Score, along with its competitors' market caps and Mohanram G-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ContraFect's Mohanram G-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ContraFect's Mohanram G-Score distribution charts can be found below:

* The bar in red indicates where ContraFect's Mohanram G-Score falls into.



ContraFect Mohanram G-Score Calculation

The calculation of the Mohanram G-score consists of eight criteria. Assign one point for each criterion met, then add up all the points to get the G-Score.

Profitability

Question 1. Return on Assets (ROA)

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. It measures how well a company uses its asset to generate earnings.

Score 1 if ROA > ROA Industry Median, 0 otherwise.

Question 2. Cash ROA

Cash ROA equals to Cash Flow from Operations divided by average Total Assets. It measures how well a company uses its asset to generate cash.

Score 1 if Cash ROA > Cash ROA Industry Median, 0 otherwise.

Question 3. CFO and Net Income

Score 1 if CFO > Net Income, 0 otherwise.

Earnings Predictability

Question 4. Earnings Variability

Earnings Variability is measured as the variance of a firm's ROA in the past five years.

Score 1 if Earnings Variability < Earnings Variability Industry Median, 0 otherwise.

Question 5. Sales Growth Variability

Sales Growth Variability is measured as the 5-year variance in sales growth.

Score 1 if Sales Growth Variability < Sales Growth Variability Industry Median, 0 otherwise.

Accounting Conservatism

Question 6. Research & Development Intensity

Research & Development Intensity is calcualted by Research & Development divided by the beginning Total Assets.

Score 1 if Research & Development Intensity > Research & Development Intensity Industry Median, 0 otherwise.

Question 7. CAPEX Intensity

CAPEX Intensity is calcualted by Capital Expenditure divided by the beginning Total Assets.

Score 1 if CAPEX Intensity > CAPEX Intensity Industry Median, 0 otherwise.

Question 8. Advertising Expenditure Intensity

Advertising Expenditure Intensity is calcualted by Advertising Expenditure divided by the beginning Total Assets. Note that Advertising Expenditure is not reported as a seperate line item for many companies, thus Selling, General, & Admin. Expense is used in this calculation.

Score 1 if Advertising Expenditure Intensity > Advertising Expenditure Intensity Industry Median, 0 otherwise.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note that all the Industry Median used for comparison in his original research, are substituted with Sector Median due to the limitation of data within certain countries.

Good or high score = 6, 7, 8
Bad or low score = 0, 1

ContraFect  (OTCPK:CFRXQ) Mohanram G-Score Explanation

Partha Mohanram is the John H. Watson Chair in Value Investing at Rotman and the Acting Vice-Dean of Research Strategy and Resources.

In 2000, he wrote a research paper called "Separating Winners from Losers Among Low Book-to-Market Stocks Using Financial Statement Analysis".

This paper tests whether a strategy based on financial statement analysis of low book-to-market (growth) stocks is successful in differentiating between winners and losers in terms of future stock performance. Based on the research, a strategy based on buying high G-score (6, 7 or 8) firms and shorting low G-score (0 or 1) firms consistently earns significant excess returns. Further, the results do not support a risk based explanation for the book-to-market effect as the strategy returns positive returns in all years, and firms that ex-ante appear less risky have better future returns.

To conclude, one can use a modified fundamental analysis strategy (G-score) to identify mispricing and earn substantial abnormal returns.


ContraFect Mohanram G-Score Related Terms

Thank you for viewing the detailed overview of ContraFect's Mohanram G-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ContraFect (ContraFect) Business Description

Traded in Other Exchanges
N/A
Address
28 Wells Avenue, 3rd Floor, Yonkers, NY, USA, 10701
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Executives
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Lishan Aklog director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Michael Messinger officer: VP Finance 238 PENNINGTON HARBURTON ROAD, PENNINGTON NJ 08534
Cary Sucoff director 1612 EAST CAPE CORAL PKWY, C/O LEGACY EDUCATION ALLIANCE, INC., CAPE CORAL FL 33904
David N. Low director EMBARCADERO FOUR, SUITE 650, SAN FRANCISCO CA 94111
Sol J Barer director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Lisa Ricciardi director C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Joshua B Muntner officer: SVP Business Development 30 FIFTH AVENUE, 12F, NEW YORK NY 10011
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 10 percent owner BUILDING A, NO. 1289 YISHAN ROAD, SHANGHAI F4 200233
Fosun Industrial Co., Ltd 10 percent owner FLAT/ROOM 808, ICBC TOWER, 3 GARDEN ROAD, HONG KONG F4 00000
Cara M Cassino officer: Chief Medical Officer 757 STONY POINT ROAD, BENSON VT 05743
Natalie Bogdanos officer: General Counsel 207-23 DARREN DRIVE, BAYSIDE NY 11360
Roger Pomerantz director 711 HARVEST HILL ROAD, CHALFONT PA 18914
Michael J. Otto director 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421